Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | TNKS | O95271 | 2/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21977136 | 0.97 | LIMK1 (0.36) | LIMK1PIM1PIM2PIM3TNKS | |
| SCHEMBL22708812 | 0.93 | LIMK1 (0.36) | LIMK1PIM1PIM2PIM3TNKS | |
| SCHEMBL22708722 | 0.93 | LIMK1 (0.36) | LIMK1PIM1PIM2PIM3TNKS | |
| SCHEMBL17297533 | 0.93 | TNKS (0.33) | LIMK1TNKSTNKS2 | |
| SCHEMBL22708667 | 0.92 | LIMK1 (0.38) | LIMK1PIM1PIM2PIM3TNKS | |
| SCHEMBL22708750 | 0.92 | LIMK1 (0.35) | LIMK1PIM1PIM2PIM3TNKS | |
| SCHEMBL20382648 | 0.92 | LIMK1 (0.31) | LIMK1PIM1PIM2PIM3 | |
| SCHEMBL18132456 | 0.91 | LIMK1 (0.34) | LIMK1PIM1PIM2PIM3 | |
| SCHEMBL17297540 | 0.91 | TNKS (0.32) | LIMK1TNKSTNKS2 | |
| SCHEMBL22708706 | 0.90 | LIMK1 (0.36) | LIMK1PIM1PIM2PIM3TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11588110-B2 | Heterocyclic compound and organic light emitting device comprising the same | LT MATERIALS CO., LTD. (KR) | 2023-02-21 | — | — | US | disclosed |
| US-11056541-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. | 2021-07-06 | — | — | US | disclosed |
| US-20200373499-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LT MATERIALS CO., LTD. (KR) | 2020-11-26 | — | — | US | disclosed |
| US-20200144337-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11588110-B2 | Heterocyclic compound and organic light emitting device comprising the same | CRY1, CYP1A1, CYP1B1 | LIMK1 541/4885PIM1 1126/4885PIM2 1936/4885 |
| US-20200373499-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | CRY1, CYP1A1, CYP1B1 | LIMK1 541/4885PIM1 1126/4885PIM2 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.